State leaders give Connecticut schools easier access to grants for HVAC improvements
Efforts to improve indoor air quality in schools has been a longstanding priority for local leaders, with many noting the negative effects of aging ventilation systems servicing school buildings constructed in the mid or late 20th century.
Can AI help solve Hartford's pothole problem?
A lack of sufficient air conditioning means schools are often forced to close due to extreme heat. Worn-down ventilation systems can be ineffective when it comes to removing dust particles that carry disease and agitate the lungs of asthmatic students.
The pandemic put those shortcomings centerstage, and state leaders rushed to act. Starting in 2022, the state government doled out $178 million in grants to help schools upgrade or replace their heating, ventilation, and air conditioning (HVAC) systems, with 163 schools receiving funds.
Though the height of the pandemic is now in the rearview window, leaders still hoped to address the longer-term issue of air quality and climate control that still poses challenges for schools across the state. The response to those calls for improvements came in the form of a policy change that state leaders framed as a more permanent, consistent fix.
Rather than distributing funds through ad hoc grant programs, cash for school HVAC upgrades will now be included as part of the state's school construction funding system. The HVAC grants under the school construction program will be easy to apply for, Commissioner Michelle Gilman, the official who oversees the program, said.
'It's a monthly application,' Gilman explained. 'It's not a competitive grant program. So, again we have made this very easy for our school districts to demonstrate the need and apply for that.'
Gilman and Lt. Gov. Susan Bysiewicz (D) visited a school in Bristol which received money as part of the earlier grants to tout the new funding arrangement.
'We've eliminated having to cancel school because of extremely hot days,' Peter Fusco, Bristol Public Schools Director of Facilities, said of the system that has been installed in South Side School.
Bysiewicz applauded the work done in Bristol and the coming funds for other districts. She noted the dual utility of the new systems — taming the effects of extreme temperatures while not losing focus of one of the original forces that drove the state spending.
'The public health benefits are really strong as well,' Bysiewicz said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data. AUSTIN, Texas, July 03, 2025--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. "It's generally assumed that AI can only make accurate predictions if it has seen similar data before," said Dr. Jennifer Bath, CEO of ImmunoPrecise. "But this benchmark proves otherwise: LENSai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate - it just needs the right kind." LENSai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENSai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. In a new benchmark study, LENSai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENSai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology. The consistent performance on entirely new, unseen complexes confirms that LENSai's artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. This breakthrough demonstrates LENSai's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. Why This Benchmark Matters In the new study, LENSai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. What It Means for Partners and Investors With LENSai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of AI-driven antibody therapeutics. For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENSai Epitope Mapping. The first highlights performance on a "seen" target, where the system was trained on related data. The second - featured in this press release - demonstrates LENSai's breakthrough ability to accurately map binding sites on a completely "unseen" target, with no prior exposure to the antibody, the antigen, or their structure. New Case Study: LENSai Epitope Mapping on an "Unseen" Target [link] Previous Case Study: Head-to-Head Benchmark on a "Seen" Target [link] These examples underscore how LENSai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or by statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances. View source version on Contacts Investor Relations Contact Louie TomaManaging Director, CORE IRinvestors@ Sign in to access your portfolio
CNN
4 hours ago
- CNN
A couple tried for 18 years to get pregnant. AI made it happen
AI Maternal health Women's health FacebookTweetLink After trying to conceive for 18 years, one couple is now pregnant with their first child thanks to the power of artificial intelligence. The couple had undergone several rounds of in vitro fertilization, or IVF, visiting fertility centers around the world in the hopes of having a baby. The IVF process involves removing a woman's egg and combining it with sperm in a laboratory to create an embryo, which is then implanted in the womb. But for this couple, the IVF attempts were unsuccessful due to azoospermia, a rare condition in which no measurable sperm are present in the male partner's semen, which can lead to male infertility. A typical semen sample contains hundreds of millions of sperm, but men with azoospermia have such low counts that no sperm cells can be found, even after hours of meticulous searching under a microscope. So the couple, who wish to remain anonymous to protect their privacy, went to the Columbia University Fertility Center to try a novel approach. It's called the STAR method, and it uses AI to help identify and recover hidden sperm in men who once thought they had no sperm at all. All the husband had to do was leave a semen sample with the medical team. 'We kept our hopes to a minimum after so many disappointments,' the wife said in an emailed statement. Researchers at the fertility center analyzed the semen sample with the AI system. Three hidden sperm were found, recovered and used to fertilize the wife's eggs via IVF, and she became the first successful pregnancy enabled by the STAR method. The baby is due in December. 'It took me two days to believe I was actually pregnant,' she said. 'I still wake up in the morning and can't believe if this is true or not. I still don't believe I am pregnant until I see the scans.' Artificial intelligence has advanced the field of fertility care in the United States: More medical facilities are using AI to help assess egg quality or screen for healthy embryos when patients are undergoing IVF. There's still more research and testing needed, but AI may now be making advancements in male infertility, in particular. Dr. Zev Williams, director of the Columbia University Fertility Center, and his colleagues spent five years developing the STAR method to help detect and recover sperm in semen samples from people who had azoospermia. They were struck by the system's results. 'A patient provided a sample, and highly skilled technicians looked for two days through that sample to try to find sperm. They didn't find any. We brought it to the AI-based STAR System. In one hour, it found 44 sperm. So right then, we realized, 'Wow, this is really a game-changer. This is going to make such a big difference for patients,' ' said Williams, who led the research team. When a semen sample is placed on a specially designed chip under a microscope, the STAR system – which stands for Sperm Tracking and Recovery – connects to the microscope through a high-speed camera and high-powered imaging technology to scan the sample, taking more than 8 million images in under an hour to find what it has been trained to identify as a sperm cell. The system instantly isolates that sperm cell into a tiny droplet of media, allowing embryologists to recover cells that they may never have been able to find or identify with their own eyes. 'It's like searching for a needle scattered across a thousand haystacks, completing the search in under an hour and doing it so gently, without any harmful lasers or stains, that the sperm can still be used to fertilize an egg,' Williams said. 'What's remarkable is that instead of the usual [200 million] to 300 million sperm in a typical sample, these patients may have just two or three. Not 2 [million] or 3 million, literally two or three,' he said. 'But with the precision of the STAR system and the expertise of our embryologists, even those few can be used to successfully fertilize an egg.' It's estimated that the male partner accounts for up to 40% of all infertility cases in the United States, and up to 10% of men with infertility are azoospermic. 'This often is a really heartbreaking and shocking and unexpected diagnosis,' Williams said. 'Most men who have azoospermia feel completely healthy and normal. There's no impairment of their sexual function, and the semen looks normal, too. The difference is that when you look at it under a microscope, instead of seeing literally hundreds of millions of sperm swimming, you just see cell debris and fragments but no sperm.' Treatment options for azoospermia traditionally have included uncomfortable surgery to retrieve sperm directly from a patient's testes. 'A part of the testes gets removed and broken into little pieces, and you try to find sperm there,' Williams said. 'It's invasive. You can only do it a couple of times before there could be permanent scarring and damage to the testes, and it's painful.' Other treatment options may include prescription hormone medications – but that will be effective only if the person has an imbalance of hormones. If no other treatment options are successful, couples may use donor sperm to have a child. Williams said the STAR method can be a new option. 'It really was a team effort to develop this, and that's what really drove and motivated everybody, the fact that you can now help couples who otherwise couldn't have that opportunity,' he said. Although the method is currently available only at the Columbia University Fertility Center, Williams and his colleagues want to publish their work and share it with other fertility centers. Using the STAR method to find, isolate and freeze sperm for a patient would cost a little under $3,000 total, he said. 'Infertility is unique in a way in that it's such an ancient part of the human experience. It's literally biblical. It's something we've had to contend with through all of human history,' he said. 'It's amazing to think that the most advanced technologies that we currently have are being used to solve this really ancient problem.' It's not the first time doctors have turned to AI to help men with azoospermia. A separate research team in Canada built an AI model that could automate and accelerate the process of searching for rare sperm in samples from men with the condition. 'The reason AI is so well-suited for this is AI really relies on learning – showing it an image of what a sperm looks like, what the shape is, what characteristics it should have – and then being able to use that learning algorithm to help identify that specific image that you're looking for,' said Dr. Sevann Helo, a urologist at Mayo Clinic with specialty interest in male infertility and male sexual dysfunction, who was not involved in the STAR method or the research in Canada. 'It's very exciting,' she said. 'AI, in general, at least in the medical community, I think is a whole new landscape and really will revolutionize the way we look at a lot of problems in medicine.' The STAR method is a novel approach to identifying sperm, but AI has been used in many other ways within fertility medicine too, said Dr. Aimee Eyvazzadeh, a San Francisco-based reproductive endocrinologist and host of the podcast 'The Egg Whisperer Show.' 'AI is helping us see what our eyes can't,' Eyvazzadeh, who was not involved in the development of STAR, wrote in an email. For instance, AI algorithms, such as one called Stork-A, have been used to analyze early-stage embryos and predict with 'surprising accuracy' which ones are likely to be healthy. Another AI tool, CHLOE, can assess the quality of a woman's eggs before she may freeze them for future use. 'AI is being used to personalize IVF medication protocols, making cycles more efficient and less of a guessing game. It's also helping with sperm selection, identifying the healthiest sperm even in difficult samples. And AI can now even predict IVF success rates with more precision than ever before, using massive data sets to give patients personalized guidance,' Eyvazzadeh said. 'The common thread? Better decisions, more confidence, and a more compassionate experience for patients.' The new STAR system is 'a game-changer,' she said. 'AI isn't creating sperm – it's helping us find the rare, viable ones that are already there but nearly invisible,' she said. 'It's a breakthrough not because it replaces human expertise, but because it amplifies it – and that's the future of fertility care.' But there is also a growing concern that the rushed application of AI in reproductive medicine could give false hope to patients, said Dr. Gianpiero Palermo, professor of embryology and director of andrology and assisted fertilization at Weill Cornell Medicine. 'AI is gaining a lot of traction nowadays to offer unbiased evaluation on embryos by looking at embryo morphology,' Palermo said in an email. 'However, current available models are still somewhat inconsistent and require additional validation.' Palermo said the STAR approach needs to be validated and would still require human embryologists to pick up sperm and inject them into an egg to create an embryo for patients undergoing IVF. 'Maybe the AI addition may help to retrieve the spermatozoon a little faster and maybe one more than the embryologist,' said Palermo, who was not involved in the development of STAR but was the first to describe the method of injecting sperm directly into an egg. Since he pioneered that method, it has become the most-utilized assisted reproductive technology in the world. 'In my opinion, this approach is faulty because inevitably some men will have no spermatozoa,' Palermo said of the STAR method, 'doesn't matter how their specimens are screened whether by humans or a machine.'
Yahoo
4 hours ago
- Yahoo
AI gives birth to fresh hope against male infertility
Artificial intelligence could make all the difference for would-be parents undergoing IVF and who are struggling with the most severe forms of male infertility. The first Australian study of new technology has led to one live birth and five pregnancies in 12 months among 35 couples who would previously be considered infertile. "These are the most difficult cases that we see at an IVF clinic, so it's very motivating to be able to help people that in a normal world, naturally would never ever be able to have their own children," IVF Australia embryologist Dale Goss told AAP. "It's great to see translation from a science project, essentially a few years ago, and a proof of concept into something that's delivered in the clinic and actually see a healthy baby boy born." The NeoGenix Biosciences employee presented the findings from the first AI SpermSearch clinical study to the European Society of Human Reproduction and Embryology conference in Paris overnight. The system works by searching for the best sperm in semen samples taken from biopsies, offering embryologists another tool to select the most appropriate sperm to be used in IVF. Mr Goss said embryologists could often spend up to six hours looking for enough of the right tiny swimmers but the technology was shown to reduce search times by 75 per cent. "We found that our reducing the time to search, we were able to get through more samples, find more sperm and give these patients a better chance at having their own biological children," he said. The technology was given early access approval for research purposes at Sydney-based Virtus Health but Mr Goss hopes it could be approved for wider use across Australia by the end of the year. About 16 per cent of couples struggle with fertility, according to Family Planning NSW, while 1 in 18 babies in Australia are born through IVF each year. NSW couple Marcela and Rowan Moon experienced infertility until tests confirmed Mr Moon's semen had no sperm because of a genetic condition. "When they told us that Rowan was infertile, I thought 'oh my God I can't have a child with Rowan being the father biologically' and then they said 'no, it's not like that, we can still do it'," Ms Moon said. Mr Moon had a biopsy as a day procedure and doctors took a sample, which was then used to create embryos. The first transfer was hailed a success and the couple later welcomed son Leo. "We were so lucky to get Leo first off the bat ... I don't think we really realised the rollercoaster that it was going to be," Mr Moon said.
